NCT02575222View on ClinicalTrials.gov

Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma

PHASE1CompletedINTERVENTIONAL

Enrollment

17

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

June 9, 2020

Study Completion Date

June 9, 2020

Conditions

Clear Cell Renal Cell Carcinoma

Interventions

DRUG

Nivolumab

3 mg/kg, IV (in the vein) on day 1 of each 2-week cycle, for a total of 3 doses prior to nephrectomy.

Trial Locations (1)

21287

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER